$CORT

CORCEPT THERAPEUTICS INC

Corcept Therapeutics is a commercial-stage company that discovers and develops medications for severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating cortisol. It markets Korlym and a generic version of Korlym in the United States for patients with hypercortisolism, selling through representatives who call on physicians. Its patient support programs help patients access treatment. Corcept also develops selective cortisol modulators, including relacorilant, nenocorilant, miricorilant and dazucorilant, for potential use in hypercortisolism, cancers, MASH and ALS. The company makes money by selling its Products. It relies on contract manufacturers to produce its Products and product candidates. Corcept Therapeutics is headquartered in Redwood City, California.

2
0
0
—
$2.8M
Maduck Sean
100%
See all $CORT insider activity →

Teva opposes Corcept's summary judgment motion in US antitrust litigation

Teva Pharmaceuticals opposed Corcept Therapeutics' motion for summary judgment in a U.S. antitrust lawsuit. Teva claims Corcept's exclusive-dealing agreements for its Cushing's syndrome treatment, Korlym, unfairly block competition. Teva argues a jury could find these agreements substantially foreclose the market.

Maduck Sean sold $2.0M of CORT

Maduck Sean sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $81.85 ($81.42–$82.68, $2.05M total) across 3 trades over 2026-11-02 to 2026-11-03 under a Rule 10b5-1 trading plan.

CORT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CORT (CORCEPT THERAPEUTICS INC). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent CORT coverage spans financial news, earnings and insider activity.

In the last 30 days, CORT insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($2.8M). The most active reporter was Maduck Sean with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving CORT

  • Early, single‑patient efficacy could spark optimism but remains speculative.

    tradingview.com · Nov 16, 2026

  • If the court denies Corcept's motion, the company may face continued litigation risk, but a denial could also validate its exclusive‑dealing strategy.

    mlex.com · Nov 7, 2026

  • The insider sale may signal reduced confidence and could pressure the stock.

    SEC EDGAR · Nov 5, 2026

  • The insider sale may be interpreted as a modest negative signal, potentially exerting slight downward pressure on the stock.

    SEC EDGAR · Nov 5, 2026

  • Piper Sandler kept its Overweight rating on Corcept Therapeutics and increased its price target to $173 from $165, suggesting a 111.2% upside from the Nov 3 close of $81.93, according to the firm.

    tradingview.com · Nov 4, 2026

AlphAI scores every news story that mentions CORT with an AI model for sentiment and relevance, and aggregates insider trades from CORCEPT THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CORT

Score
$CORTMedEarnings

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

CORCEPT THERAPEUTICS INC (CORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update • Revenue of $340.5 million, a 64 percent increase over the same period in 2025 ◦ Korlym ® and authorized generic product revenue of $249.1 million ◦ Lifyorli ® product reven

Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks

Corcept (CORT) reported Q2 revenues of $256.1M, up 31.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing expectations. Bristol-Myers Squibb (BMY) reported $12.97B in revenues, up 5.7% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market focus has shifted from AI to geopolitics and back to fundamentals.

Related tickers